TY - JOUR A1 - Suliman, Salwa A1 - Sun, Yang A1 - Pedersen, Torbjorn O. A1 - Xue, Ying A1 - Nickel, Joachim A1 - Waag, Thilo A1 - Finne-Wistrand, Anna A1 - Steinmüller-Nethl, Doris A1 - Krueger, Anke A1 - Costea, Daniela E. A1 - Mustafa, Kamal T1 - In vivo host response and degradation of copolymer scaffolds functionalized with nanodiamonds and bone morphogenetic protein 2 JF - Advanced Healthcare Materials N2 - The aim is to evaluate the effect of modifying poly[(L-lactide)-co-(epsilon-caprolactone)] scaffolds (PLCL) with nanodiamonds (nDP) or with nDP+physisorbed BMP-2 (nDP+BMP-2) on in vivo host tissue response and degradation. The scaffolds are implanted subcutaneously in Balb/c mice and retrieved after 1, 8, and 27 weeks. Molecular weight analysis shows that modified scaffolds degrade faster than the unmodified. Gene analysis at week 1 shows highest expression of proinflammatory markers around nDP scaffolds; although the presence of inflammatory cells and foreign body giant cells is more prominent around the PLCL. Tissue regeneration markers are highly expressed in the nDP+BMP-2 scaffolds at week 8. A fibrous capsule is detectable by week 8, thinnest around nDP scaffolds and at week 27 thickest around PLCL scaffolds. mRNA levels of ALP, COL1 alpha 2, and ANGPT1 are signifi cantly upregulating in the nDP+BMP-2 scaffolds at week 1 with ectopic bone seen at week 8. Even when almost 90% of the scaffold is degraded at week 27, nDP are observable at implantation areas without adverse effects. In conclusion, modifying PLCL scaffolds with nDP does not aggravate the host response and physisorbed BMP-2 delivery attenuates infl ammation while lowering the dose of BMP-2 to a relatively safe and economical level. KW - inflammatory response KW - biocompatibility KW - BMP-2 delivery KW - inflammation KW - tissue engineering Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-189764 VL - 5 IS - 6 ER - TY - THES A1 - Waag, Thilo T1 - Funktionalisierung von Nanodiamanten für Wirkstofftransport und Knochenersatzmaterialien T1 - Functionalization of nanodiamonds for drug delivery and alternate bone material N2 - Ziel der vorliegenden Arbeit ist das Design, die Synthese und das anschließende Testen von Nanodiamant-Wirkstoff-Konjugaten. Dafür müssen zunächst Nanodiamanten mit geeigneten Linkersystemen funktionalisiert werden, um anschließend verschiedene pharmazeutische Wirkstoffe auf der Diamantoberfläche zu immobilisieren. Die Wirksamkeit der so angebundenen Inhibitoren auf die verschiedenen Erreger muss anschließend in vitro und in vivo getestet werden. Auch die Art der Aufnahme der Nanodiamanten in die verschiedenen Zellen muss untersucht werden. Dazu sollen Fluoreszenzfarbstoffe, wie z.B. Oregon Green 488, auf der Diamantoberfläche immobilisiert werden. N2 - Because of its low toxicity and rich surface chemistry nanodiamond is well suited for the application in the fields of biology and medicine. The aim of this work is the development of various nanodiamond conjugates as drug delivery systems and components of bone replacement materials. Before the immobilization of drugs the nanodiamond particles need to be functionalized with acid labile linker systems, in this case hydrazones. After entering the acidic cell compartments the drug is released. First of all, the linkers are isolated as diazonium-tetrafluoroborates and after that immobilized on mechanically deagglomerated nanodiamond. The drugs can be bound to the hydrazine linker systems. In this work several drugs are immobilized to the nanodiamond surface via hydrazine linker systems and the drug release under acidic conditions is analyzed. Further compounds are immobilized for the investigation for future bone replacement materials, namely dyes and growth factors. KW - Nanodiamant KW - nanomateriales KW - nanotherapeutics KW - Diamant KW - Nanostrukturiertes Material KW - Wirkstofffreisetzung KW - Knochenersatz Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-94597 ER - TY - JOUR A1 - Suliman, Salwa A1 - Mustafa, Kamal A1 - Krueger, Anke A1 - Steinmüller-Nethl, Doris A1 - Finne-Wistrand, Anna A1 - Osdal, Tereza A1 - Hamza, Amani O. A1 - Sun, Yang A1 - Parajuli, Himalaya A1 - Waag, Thilo A1 - Nickel, Joachim A1 - Johannessen, Anne Christine A1 - McCormack, Emmet A1 - Costea, Daniela Elena T1 - Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes JF - Biomaterials N2 - This study aimed to evaluate the tumorigenic potential of functionalising poly(LLA-co-CL) scaffolds. The copolymer scaffolds were functionalised with nanodiamonds (nDP) or with nDP and physisorbed BMP-2 (nDP-PHY) to enhance osteoinductivity. Culturing early neoplastic dysplastic keratinocytes (DOK\(^{Luc}\)) on nDP modified scaffolds reduced significantly their subsequent sphere formation ability and decreased significantly the cells' proliferation in the supra-basal layers of in vitro 3D oral neoplastic mucosa (3D-OT) when compared to DOK\(^{Luc}\) previously cultured on nDP-PHY scaffolds. Using an in vivo non-invasive environmentally-induced oral carcinogenesis model, nDP scaffolds were observed to reduce bioluminescence intensity of tumours formed by DOK\(^{Luc}\) + carcinoma associated fibroblasts (CAF). nDP modification was also found to promote differentiation of DOK\(^{Luc}\) both in vitro in 3D-OT and in vivo in xenografts formed by DOKLuc alone. The nDP-PHY scaffold had the highest number of invasive tumours formed by DOK\(^{Luc}\) + CAF outside the scaffold area compared to the nDP and control scaffolds. In conclusion, in vitro and in vivo results presented here demonstrate that nDP modified copolymer scaffolds are able to decrease the tumorigenic potential of DOK\(^{Luc}\), while confirming concerns for the therapeutic use of BMP-2 for reconstruction of bone defects in oral cancer patients due to its tumour promoting capabilities. KW - Bone morphogenetic protein-2 KW - Sinus floor augmentation KW - Marrow stromal cells KW - Growth; BMP-2 KW - Tumorigenicity KW - Biodegradable polymer scaffolds KW - Mandibular continuity defects KW - Squamous-cell carcinoma KW - In-vitro KW - Mesenchymal transition KW - BMP-2 KW - Bone tissue engineering KW - Biocompatibility KW - Microenvironment KW - Oral squamous cell carcinoma Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-188287 VL - 95 ER -